Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy

Summary

To add an increased level of safety to antihemophilic factor replacement therapy, a full-length, recombinant Factor VIII (rFVIII) product has been developed without human-derived plasma proteins during purification and formulation and using an additional solvent/detergent viral inactivation step. This first clinical trial of a sucrose-formulated full-length rFVIII (rFVIII-FS) was conducted in previously treated patients (≥100 prior exposure days) with severe (<2% FVIII) hemophilia A in North America (NA) and Europe (EU). Pharmacokinetic profiles for rFVIII-FS were compared with those of currently licensed rFVIII product (Kogenate^®) in 35 patients. Safety and efficacy during home therapy were evaluated in 71 patients. The new formulation displayed a pharmacokinetic profile similar to that of rFVIII. Patients on home therapy received a cumulative total of 11,867 exposure days, 12,546 infusions, and 22,443,694 IU of rFVIII-FS. Of 2585 bleeds, 93.5% were treated with 1-2 infusions and 80.5% of responses were rated as excellent or good. No evidence of de novo inhibitor formation was observed. Only 0.27% of infusions were associated with any drugrelated adverse event. Except for an episode of intermittent chest pain with palpitations which ceased after treatment with analgesics, associated adverse events were mild or moderate. Overall, rFVIII-FS provided excellent hemostatic control, was well-tolerated, and caused no significant adverse effects, thus demonstrating safety and efficacy for treatment of bleeds in patients with hemophilia A.

Key words

Hemophilia A - recombinant Factor VIII - full-length rFVIII

^* Members of the International Kogenate-FS Study Group Writing Committee participated equally in development of this manuscript.

• References

• 1 Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. Haemophilia 1999; 05: 9-16.
• 2 Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 05: 145-54.
• 3 Brackmann HH, Oldenburg J, Eis-Hubinger AM, Gerritzen A, Hammerstein U, Hanfland P. Hepatitis A virus infection among the hemophilia population at the Bonn Hemophilia Center. Vox Sang 1994; 67 (Suppl. 01) 3-7.
• 4 Mannucci PM, Gdovin S, Gringeri A, Colombo M, Mele A, Schinaia N, Ciavarella N, Emerson SU, Purcell RH. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med 1994; 120: 1-7.
• 5 Lawlor E, Johnson Z, Thornton L, Temperley I. Investigation of an outbreak of hepatitis A in Irish haemophilia A patients. Vox Sang 1994; 67 (Suppl. 01) 18-9.
• 6 Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt BL. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion 1998; 38: 573-9.
• 7 Aguilar CFranco, Lucia JFCuesta, Ferrer JTorres, Omenaca MTeres. Parvovirus B19 infection in patients with congenital blood coagulation disorders. Med Clin (Barc) 1997; 108: 641-6.
• 8 Santagostino E, Mannucci PM, Gringeri A, Azzi A, Morfini M, Musso R, Santoro R, Schiavoni M. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion 1997; 37: 517-22.
• 9 Lefrere JJ, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet 1994; 343: 211-2.
• 10 Azzi A, Ciappi S, Zakvrzewska K, Morfini M, Mariani G, Mannucci PM. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992; 39: 228-30.
• 11 Chamberland M, Khabbaz RF. Emerging issues in blood safety. Infect Dis Clin North Am 1998; 12: 217-29.
• 12 Vrielink H, Reesink H. Transfusion-transmissible infections. Curr Opin Hematol 1998; 05: 396-405.
• 13 International Society on Thrombosis and Haemostasis Factor VIII and Factor IX Subcommittee. Recommendations on plasma and concentrate units and in vivo recovery. Florence; Italy: 1997
• 14 Klein U. Kogenate TM – Antihemophilic factor (recombinant) (BHK): preclinical, production and quality assurance. Proc Int Symp Hemophilia Treatment 1990; 06: 1-13.
• 15 Boedeker BG. The manufacturing of the recombinant factor VIII, Kogenate. Transfus Med Rev 1992; 06: 256-60.
• 16 The European Agency for the Evaluation of Medicinal Products. Note for guidance to assess efficacy and safety of human plasma derived factor VIII: C and factor IX: C products in clinical trials in haemophiliacs before and after authorisation. CPMP/BPWP 1995; 198.
• 17 Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 1991; 66: 384-6.
• 18 Ljung RCR. Prophylactic infusion regimens in the management of hemophilia. Thromb Haemost 1999; 82: 525-30.
• 19 Scandella D, Mondorf W, Klinge J. The natural history of the immune response to exogenous factor VIII in severe haemophilia A. Haemophilia 1998; 04: 546-51.
• 20 Scharrer I, Brackmann HH, Sultan Y, Abshire T, Ragni M, Gorina E, Hurst D, Kellermann E. Efficacy of a sucrose formulated recombinant factor VIII (rFVIII-SF) used for 11 surgical procedures ranging from tooth extraction to brain tumour excision in severe hemophilia A patients. Haemophilia 1998; 04: 186.
• 21 Kimball JA, Norman DJ, Shield CF, Schroeder TJ, Lisi P, Garovoy M, O’Connell JB, Stuart F, McDiarmid SV, Wall W. The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Transpl Immunol 1995; 03: 212-21.
• 22 Buist MR, Kenemans P, van Kamp GJ, Haisma HJ. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol Immunother 1995; 40: 24-30.
• 23 Sakahara H, Saga T, Onodera H, Yao Z, Nakamoto Y, Zhang M, Sato N, Nakada H, Yamashina I, Endo K, Konishi J. Anti-murine antibody response to mouse monoclonal antibodies in cancer patients. Jpn J Cancer Res 1997; 88: 895-9.
• 24 Naoumov NV, Petrova EP, Thomas MG, Williams R. Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet 1998; 352: 195-7.
• 25 De Filippi F, Colombo M, Rumi MG, Tradati F, Prati D, Zanella A, Mannucci PM. High rates of hepatitis G virus infection in multitransfused patients with hemophilia. Blood 1997; 90: 4634-7.
• 26 Martindale – The Extra Pharmacopoeia. 21. London: Royal Pharmaceutical Society; 1996
• 27 Armstrong N, Pickard A, Hamlow E. Sucrose. In: Handbook of Pharmaceutical Excipients. 2. Wade A, Weller P. eds. Washington: American Pharmaceutical Association; 1994: 500-5.